Outcomes of an automated procedure for the selection of effective platelets for patients refractory to random donors based on cross‐matching locally available platelet products
Paolo Rebulla(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Nicoletta Revelli, Angela Nocco(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), N. Greppi(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Agostino Cortelezzi(Istituti di Ricovero e Cura a Carattere Scientifico), Giovanni Martinelli(University of Bologna), Cinzia Paccapelo(University of Milan), Maurizio Marconi(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Fernanda Morelati(Organ Transplantation and Immunology Institute), Nicola Fracchiolla(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Maria Antonietta Villa
Cited by 36
Related Papers
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
|Blood|2015|1.2k
Levofloxacin to Prevent Bacterial Infection in Patients with Cancer and Neutropenia
|New England Journal of Medicine|2005|644